Cyclopentolate
- Atc Codes:S01FA04
- CAS Codes:5870-29-1#512-15-2
- PHARMGKB ID:5870-29-1#512-15-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Cyclopentolat; Belgium: Cyclogyl, Cyclopentolate; Bulgaria: Cyclogyl; Cyprus: Cyclogyl; Denmark: Cyclogyl; Estonia: Cyclogyl; Finland: Oftan-Syklo; France: Skiacol; Germany: Cyclopentolat, Zyklolat Edo; Greece: Cyclogyl; Hungary: Humapent; Ireland: Cyclopentolate, Mydrilate; Italy: Ciclolux; Latvia: Cyclogyl; Lithuania: Cyclogyl; Luxembourg: Cyclopentolate, Cyclopentol, Zyklolat Edo; Malta: Cyclopentolate, Mydrilate; Netherlands: Cyclogyl, Cyclopentolaat; Portugal: Cicloplegicedol, Midriodavi; Spain: Ciclopegic Colirio, Colicursi Ciclopéjico; Sweden: Cyclogyl, Cyclopentolat; UK: Cyclopentolate, Mydrilate.
North America
Canada: AK-Pentolate, Cyclogyl, Diopentolate; USA: AK-Pentolate, Cyclogyl, Pentolair.
Latin America
Argentina: Ciclopenal, Ciclopentolato; Brazil: Ciclolato, Cicloplégico; Mexico: Refractyl Ofteno.
Asia
Japan: Cyclogyl, Cyplegin.
Drug combinations
Cyclopentolate and Phenylephrine
Chemistry
Cyclopentolate Hydrochloride: C~17~H~25~NO~3~ HCl. Mw: 327.85. (1) Benzeneacetic acid, α-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester, hydrochloride, (±)-; (2) 2-(Dimethylamino)ethyl (±)-1-hydroxy-α-phenylcyclopentaneacetate hydrochloride. CAS-5870-29-1; CAS-512-15-2 (cyclopentolate).
Pharmacologic Category
EENT Preparations; Mydriatics. Ophthalmic Anticholinergic Agent. (ATC-Code: S01FA04).
Mechanism of action
Mydriatic and cycloplegic. Shares the pharmacologic effects of atropine on the eye but has a shorter duration of action. Blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).
Therapeutic use
Diagnostic procedures requiring mydriasis and cycloplegia.
Pregnancy and lactiation implications
Animal studies not performed. Should be used during pregnancy only when clearly needed. Caution when used in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to cyclopentolate or any component of the formulation. Untreated narrow-angle glaucoma. Untreated anatomically narrow angles.
Warnings and precautions
May cause CNS disturbances, especially with the higher concentrations (children are more susceptible). May cause a transient elevation in intraocular pressure. Patients with Down syndrome are predisposed to angle-closure glaucoma (use with caution). Contains benzalkonium chloride which may be adsorbed by contact lenses. Use with caution in the elderly (higher risk of increased intraocular pressure). May result in psychotic reactions and behavioral disturbances in children, especially with the 2% solution. Feeding intolerance may occur in infants. For topical ophthalmic use only.